Diagnosis and Bacterial Identification of Periprosthetic Joint Infection With Microbial-ID
Launched by UMC UTRECHT · Apr 1, 2022
Trial Information
Current as of July 09, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
In the diagnosis of periprosthetic joint infection (PJI) there is no golden standard test. Multiple definitions for the diagnosis of PJI exist, such as the European Bone and Joint Infection Society (EBJIS)1, Musculoskeletal Infection Society (MSIS)2, and the Infectious Diseases Society of America (IDSA)3. One of the criteria that defines PJI is that there are at least two positive periprosthetic cultures with phenotypically identical organisms. Although these two positive bacterial cultures can certainly be considered proof of PJI, many other criteria are also used, such as a sinus tract, w...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient has complaints (pain, stiffness) about the prosthetic joint And has clinical features for joint infection at physical examination (swelling, redness, warm, sinus tract) AND has an elevated serum CRP (\>10 mg/L)
- • Patient is scheduled for a puncture AND/OR surgery, with harvesting of synovial fluid
- • Patient ≥ 18 years of age
- • Patient is competent, able, and willing to provide written informed consent
- Exclusion Criteria:
- • Treatment with antibiotics ≤2 weeks prior to puncture and/or surgery;
- • Other obvious reason(s) for implant dysfunction, such as: fracture, an implant breakage, a malposition, and/or a tumour.
About Umc Utrecht
UMC Utrecht is a leading academic medical center in the Netherlands, renowned for its commitment to innovative research and high-quality patient care. As a prominent sponsor of clinical trials, UMC Utrecht leverages its extensive expertise in translational medicine and collaboration with various stakeholders to advance medical knowledge and improve therapeutic outcomes. The institution emphasizes ethical conduct and rigorous scientific standards, ensuring that all research activities contribute meaningfully to the global healthcare landscape. Through its robust clinical trial infrastructure, UMC Utrecht plays a vital role in facilitating the development of new treatments and enhancing patient wellbeing.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Utrecht, , Netherlands
Barcelona, , Spain
Utrecht, , Netherlands
Lausanne, , Switzerland
Berlin, , Germany
Porto, , Portugal
Valdoltra, , Slovenia
Basel, , Switzerland
Patients applied
Trial Officials
Harrie Weinans, Prof, MD
Principal Investigator
H.H.Weinans@umcutrecht.nl
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials